SCYNEXIS completes last-patient/last-visit ahead of schedule in phase 3 study
SCYNEXIS announced completion of the last-patient/last-visit in its Phase 3 VANISH 303 study, and that it expects to release top-line data earlier than previously reported. Ibrexafungerp is the first representative of a novel family of antifungal compounds referred to as triterpenoids. September 18, 2019